Maven Health, NeoSens and NADUP supported by the FIT
Share this article
Three life science projects have received support from the Foundation for Technological Innovation (FIT) in the form of Tech Grants: Maven Health and NeoSens from EPFL, and NADUP from UNIL will be able to continue developing their technologies with the backing of the Foundation.
Maven Health – prevention and screening of metabolic diseases
Maven Health, a spin-off from EPFL, aims to revolutionise the prevention and screening of metabolic diseases, which represent a significant burden for the Swiss healthcare system. Using advanced spectroscopy technology, combined with a proprietary software platform and machine learning algorithms, Maven Health is developing a non-invasive saliva screening solution. This approach enables a comprehensive assessment of metabolic health with increased accuracy, while being less invasive and providing more actionable insights than traditional methods.
The project has the potential to radically transform the way healthcare professionals manage metabolic health, offering a more holistic and proactive solution. Maven Health has been awarded a CHF 100,000 FIT InnoGrant.
NeoSens – Diagnosing neonatal sepsis
NeoSens has designed a device to significantly improve the early diagnosis of neonatal sepsis in low- and middle-income countries. By combining artificial intelligence and biosensing technology, NeoSens offers rapid, accurate and cost-effective diagnosis. This technology represents a major advance in the fight against antibiotic resistance and the reduction of healthcare costs associated with neonatal sepsis.
NeoSens has been awarded a CHF 100,000 FIT InnoGrant.
NADUP improves the efficiency of cellular cancer treatments
NADUP, a spin-off from the University of Lausanne and the Lausanne Branch of Ludwig Institute for Cancer Research, has been awarded a CHF 100,000 FIT InnoTREK grant for its pioneering work in improving CAR-T cell therapy. This type of cancer treatment is highly effective in children and young adults, but significantly less effective in older people.
NADUP is committed to define the best rejuvenation strategy to improve current and future CAR-T cell therapies. This pioneering approach holds the potential to significantly increase the effectiveness of both existing and forthcoming therapies, offering a new way of treating cancers and other diseases.
➡️ Source: FIT